Neurofilament Light Chain Levels Interact with Neurodegenerative Patterns and Motor Neuron Dysfunction in Amyotrophic Lateral Sclerosis

References

1. 1.↵
   2. Hardiman O,
   3. Al-Chalabi A,
   4. Chio A, et al

   . Amyotrophic lateral sclerosis. Nat Rev Dis Primers 2017;3:17071–79 doi:10.1038/nrdp.2017.71 pmid:28980624

   CrossRefPubMed
2. 2.↵
   2. Grad LI,
   3. Rouleau GA,
   4. Ravits J, et al

   . Clinical spectrum of amyotrophic lateral sclerosis (ALS). Cold Spring Harb Perspect Med 2017;7:a024117 doi:10.1101/cshperspect.a024117 pmid:28003278

   Abstract/FREE Full Text
3. 3.↵
   2. Kiernan MC,
   3. Vucic S,
   4. Cheah BC, et al

   . Amyotrophic lateral sclerosis. Lancet 2011;377:942–55 doi:10.1016/S0140-6736(10)61156-7 pmid:21296405

   CrossRefPubMedWeb of Science
4. 4.↵
   2. Thorns J,
   3. Jansma H,
   4. Peschel T, et al

   . Extent of cortical involvement in amyotrophic lateral sclerosis: an analysis based on cortical thickness. BMC Neurol 2013;13:148 doi:10.1186/1471-2377-13-148 pmid:24138960

   CrossRefPubMed
5. 5.↵
   2. Mazón M,
   3. Costa JF,
   4. Ten-Esteve A, et al

   . Imaging biomarkers for the diagnosis and prognosis of neurodegenerative diseases: the example of amyotrophic lateral sclerosis. Front Neurosci 2018;12:784 doi:10.3389/fnins.2018.00784 pmid:30410433

   CrossRefPubMed
6. 6.↵
   2. Vázquez-Costa JF,
   3. Mazón M,
   4. Carreres-Polo J, et al

   . Brain signal intensity changes as biomarkers in amyotrophic lateral sclerosis. Acta Neurol Scand 2018;137:262–71 doi:10.1111/ane.12863 pmid:29082510

   CrossRefPubMed
7. 7.↵
   2. Schweitzer AD,
   3. Liu T,
   4. Gupta A, et al

   . Quantitative susceptibility mapping of the motor cortex in amyotrophic lateral sclerosis and primary lateral sclerosis. AJR Am J Roentgenol 2015;204:1086–92 doi:10.2214/AJR.14.13459 pmid:25905946

   CrossRefPubMed
8. 8.↵
   2. Verstraete E,
   3. Turner MR,
   4. Grosskreutz J, et al

   ; attendees of the 4th NiSALS meeting. Mind the gap: the mismatch between clinical and imaging metrics in ALS. Amyotroph Lateral Scler Frontotemporal Degener 2015;16:524–29 doi:10.3109/21678421.2015.1051989 pmid:26402254

   CrossRefPubMed
9. 9.↵
   2. Jin J,
   3. Hu F,
   4. Zhang Q, et al

   . Dominant heterogeneity of upper and lower motor neuron degeneration to motor manifestation of involved region in amyotrophic lateral sclerosis. Sci Rep 2019;9:20059 doi:10.1038/s41598-019-56665-8 pmid:31882886

   CrossRefPubMed
10. 10.↵
    2. Schuster C,
    3. Kasper E,
    4. Machts J, et al

    . Focal thinning of the motor cortex mirrors clinical features of amyotrophic lateral sclerosis and their phenotypes: a neuroimaging study. J Neurol 2013;260:2856–64 doi:10.1007/s00415-013-7083-z pmid:23996101

    CrossRefPubMed
11. 11.↵
    2. Khalil M,
    3. Teunissen CE,
    4. Otto M, et al

    . Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol 2018;14:577–89 doi:10.1038/s41582-018-0058-z pmid:30171200

    CrossRefPubMed
12. 12.↵
    2. Forgrave LM,
    3. Ma M,
    4. Best JR, et al

    . The diagnostic performance of neurofilament light chain in CSF and blood for Alzheimer’s disease, frontotemporal dementia, and amyotrophic lateral sclerosis: a systematic review and meta-analysis. Alzheimers Dement (Amst) 2019;11:730–43 doi:10.1016/j.dadm.2019.08.009 pmid:31909174

    CrossRefPubMed
13. 13.↵
    2. Gaiani A,
    3. Martinelli I,
    4. Bello L, et al

    . Diagnostic and prognostic biomarkers in amyotrophic lateral sclerosis: neurofilament light chain levels in definite subtypes of disease. JAMA Neurol 2017;74:525–32 doi:10.1001/jamaneurol.2016.5398 pmid:28264096

    CrossRefPubMed
14. 14.↵
    2. Rossi D,
    3. Volanti P,
    4. Brambilla L, et al

    . CSF neurofilament proteins as diagnostic and prognostic biomarkers for amyotrophic lateral sclerosis. J Neurol 2018;265:510–21 doi:10.1007/s00415-017-8730-6 pmid:29322259

    CrossRefPubMed
15. 15.↵
    2. Benatar M,
    3. Wuu J,
    4. Turner MR

    . Neurofilament light chain in drug development for amyotrophic lateral sclerosis: a critical appraisal. Brain 2022;146:2711–16 doi:10.1093/brain/awac394 pmid:36310538

    CrossRefPubMed
16. 16.↵
    2. Brodovitch A,
    3. Boucraut J,
    4. Delmont E, et al

    . Combination of serum and CSF neurofilament-light and neuroinflammatory biomarkers to evaluate ALS. Sci Rep 2021;11:703 doi:10.1038/s41598-020-80370-6 pmid:33436881

    CrossRefPubMed
17. 17.↵
    2. Verde F,
    3. Steinacker P,
    4. Weishaupt JH, et al

    . Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2019;90:157–64 doi:10.1136/jnnp-2018-318704 pmid:30309882

    Abstract/FREE Full Text
18. 18.↵
    2. Grapperon AM,
    3. Verschueren A,
    4. Jouve E, et al

    . Assessing the upper motor neuron in amyotrophic lateral sclerosis using the triple stimulation technique: a multicenter prospective study. Clin Neurophysiol 2021;132:2551–57 doi:10.1016/j.clinph.2021.08.003 pmid:34455313

    CrossRefPubMed
19. 19.↵
    2. Geevasinga N,
    3. van den Bos M,
    4. Menon P, et al

    . Utility of transcranial magnetic simulation in studying upper motor neuron dysfunction in amyotrophic lateral sclerosis. Brain Sci 2021;11:906 doi:10.3390/brainsci11070906 pmid:34356140

    CrossRefPubMed
20. 20.↵
    2. de Carvalho M,
    3. Swash M

    . Lower motor neuron dysfunction in ALS. Clin Neurophysiol 2016;127:2670–81 doi:10.1016/j.clinph.2016.03.024 pmid:27117334

    CrossRefPubMed
21. 21.↵
    2. Rutkove SB

    . Clinical measures of disease progression in amyotrophic lateral sclerosis. Neurotherapeutics 2015;12:384–93 doi:10.1007/s13311-014-0331-9 pmid:25582382

    CrossRefPubMed
22. 22.↵
    2. Vucic S,
    3. Stanley Chen KH,
    4. Kiernan MC, et al

    . The clinical diagnostic utility of transcranial magnetic stimulation: report of an IFCN committee. Clin Neurophysiol 2008;150:131–75 doi:10.1016/j.clinph.2007.10.014 pmid:18063409

    CrossRefPubMed
23. 23.↵
    2. de Carvalho M,
    3. Chio A,
    4. Dengler R, et al

    . Neurophysiological measures in amyotrophic lateral sclerosis: markers of progression in clinical trials. Amyotroph Lateral Scler Other Motor Neuron Disord 2005;6:17–28 doi:10.1080/14660820410020600 pmid:16036422

    CrossRefPubMed
24. 24.↵
    2. Brooks BR,
    3. Miller RG,
    4. Swash M, et al

    ; World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000;1:293–99 doi:10.1080/146608200300079536 pmid:11464847

    CrossRefPubMedWeb of Science
25. 25.↵
    2. Rascovsky K,
    3. Hodges JR,
    4. Knopman D, et al

    . Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 2011;134:2456–77 doi:10.1093/brain/awr179 pmid:21810890

    CrossRefPubMedWeb of Science
26. 26.↵
    2. Oldfield RC

    . The assessment and analysis of handedness: the Edinburgh inventory. Neuropsychologia 1971;9:97–113 doi:10.1016/0028-3932(71)90067-4 pmid:5146491

    CrossRefPubMedWeb of Science
27. 27.↵
    2. Fautz H,
    3. Vogel M,
    4. Gross P, et al

    . B1 mapping of coil arrays for parallel transmission. In: Proceedings of the International Society for Magnetic Resonance in Medicine. May 3–9, 2008;1247. Toronto, Ontario, Canada
28. 28.↵
    2. O’Brien KR,
    3. Kober T,
    4. Hagmann P, et al

    . Robust T1-weighted structural brain imaging and morphometry at 7T using MP2RAGE. PLoS One 2014;9:e99676 doi:10.1371/journal.pone.0099676 pmid:24932514

    CrossRefPubMed
29. 29.↵
    2. Isensee F,
    3. Schell M,
    4. Pflueger I, et al

    . Automated brain extraction of multisequence MRI using artificial neural networks. Hum Brain Mapp 2019;40:4952–64 doi:10.1002/hbm.24750 pmid:31403237

    CrossRefPubMed
30. 30.↵
    2. Desikan RS,
    3. Ségonne F,
    4. Fischl B, et al

    . An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage 2006;31:968–80 doi:10.1016/j.neuroimage.2006.01.021 pmid:16530430

    CrossRefPubMedWeb of Science
31. 31.↵
    2. Menke RAL,
    3. Gray E,
    4. Lu CH, et al

    . CSF neurofilament light chain reflects corticospinal tract degeneration in ALS. Ann Clin Transl Neurol 2015;2:748–55 doi:10.1002/acn3.212 pmid:26273687

    CrossRefPubMed
32. 32.↵
    2. Piehl F,
    3. Kockum I,
    4. Khademi M, et al

    . Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod. Mult Scler 2018;24:1046–54 doi:10.1177/1352458517715132 pmid:28627962

    CrossRefPubMed
33. 33.↵
    2. Hansson O,
    3. Janelidze S,
    4. Hall S, et al

    ; Swedish BioFINDER study, Blood-based NfL: a biomarker for differential diagnosis of parkinsonian disorder. Neurology 2017;88:930–37 doi:10.1212/WNL.0000000000003680 pmid:28179466

    Abstract/FREE Full Text
34. 34.↵
    2. Weinhofer I,
    3. Rommer P,
    4. Zierfuss B, et al

    . Neurofilament light chain as a potential biomarker for monitoring neurodegeneration in X-linked adrenoleukodystrophy. Nat Commun 2021;12:1816 PMC]doi:10.1038/s41467-021-22114-2 pmid:33753741

    CrossRefPubMed
35. 35.↵
    2. Gille B,
    3. De Schaepdryver M,
    4. Goossens J, et al

    . Serum neurofilament light chain levels as a marker of upper motor neuron degeneration in patients with amyotrophic lateral sclerosis. Neuropathol Appl Neurobiol 2019;45:291–304 doi:10.1111/nan.12511 pmid:29908069

    CrossRefPubMed
36. 36.↵
    2. Vacchiano V,
    3. Mastrangelo A,
    4. Zenesini C, et al

    . Plasma and CSF neurofilament light chain in amyotrophic lateral sclerosis: a cross-sectional and longitudinal study. Front Aging Neurosci 2021;13:753242 doi:10.3389/fnagi.2021.753242 pmid:34744694

    CrossRefPubMed
37. 37.↵
    2. El Mendili MM,
    3. Verschueren A,
    4. Ranjeva JP, et al

    . Association between brain and upper cervical spinal cord atrophy assessed by MRI and disease aggressiveness in amyotrophic lateral sclerosis. Neuroradiology 2023;65:1395–403 doi:10.1007/s00234-023-03191-0 pmid:37458788

    CrossRefPubMed
38. 38.↵
    2. Menke RA,
    3. Körner S,
    4. Filippini N, et al

    . Widespread grey matter pathology dominates the longitudinal cerebral MRI and clinical landscape of amyotrophic lateral sclerosis. Brain 2014;137:2546–55 doi:10.1093/brain/awu162 pmid:24951638

    CrossRefPubMedWeb of Science
39. 39.↵
    2. van der Ende EL,
    3. Meeter LH,
    4. Poos JM, et al

    ; Genetic Frontotemporal dementia Initiative (GENFI). Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study. Lancet Neurol 2019;18:1103–11 doi:10.1016/S1474-4422(19)30354-0 pmid:31701893

    CrossRefPubMed
40. 40.↵
    2. Bede P,
    3. Bokde A,
    4. Elamin M, et al

    . Grey matter correlates of clinical variables in amyotrophic lateral sclerosis (ALS): a neuroimaging study of ALS motor phenotype heterogeneity and cortical focality. J Neurol Neurosurg Psychiatry 2013;84:766–73 doi:10.1136/jnnp-2012-302674 pmid:23085933

    Abstract/FREE Full Text
41. 41.↵
    2. Wirth AM,
    3. Khomenko A,
    4. Baldaranov D, et al

    . Combinatory biomarker use of cortical thickness, MUNIX, and ALSFRS-R at baseline and in longitudinal courses of individual patients with amyotrophic lateral sclerosis. Front Neurol 2018;9:614 doi:10.3389/fneur.2018.00614 pmid:30104996

    CrossRefPubMed
42. 42.↵
    2. Catani M

    . A little man of some importance. Brain 2017;140:3055–61 doi:10.1093/brain/awx270 pmid:29088352

    CrossRefPubMed
43. 43.↵
    2. Muret D,
    3. Root V,
    4. Kieliba P, et al

    . Beyond body maps: Information content of specific body parts is distributed across the somatosensory homunculus. Cell Rep 2022;38:110523 doi:10.1016/j.celrep.2022.110523 pmid:35294887

    CrossRefPubMed
44. 44.↵
    2. Schellekens W,
    3. Bakker C,
    4. Ramsey NF, et al

    . Moving in on human motor cortex: characterizing the relationship between body parts with non-rigid population response fields. PLoS Comput Biol 2022;18:e1009955 doi:10.1371/journal.pcbi.1009955 pmid:35377877

    CrossRefPubMed
45. 45.↵
    2. Bergman J,
    3. Dring A,
    4. Zetterberg H, et al

    . Neurofilament light in CSF and serum is a sensitive marker for axonal white matter injury in MS. Neurol Neuroimmunol Neuroinflamm 2016;3:e271 doi:10.1212/NXI.0000000000000271 pmid:27536708

    Abstract/FREE Full Text
46. 46.↵
    2. Geraldo AF,
    3. Pereira J,
    4. Nunes P, et al

    . Beyond fractional anisotropy in amyotrophic lateral sclerosis: the value of mean, axial, and radial diffusivity and its correlation with electrophysiological conductivity changes. Neuroradiology 2018;60:505–15 doi:10.1007/s00234-018-2012-6 pmid:29564498

    CrossRefPubMed
47. 47.↵
    2. Wagner J,
    3. Weber B,
    4. Urbach H, et al

    . Morphometric MRI analysis improves detection of focal cortical dysplasia type II. Brain 2011;134:2844–54 doi:10.1093/brain/awr204 pmid:21893591

    CrossRefPubMed
48. 48.↵
    2. Wang ZI,
    3. Alexopoulos AV,
    4. Jones SE, et al

    . Linking MRI postprocessing with magnetic source imaging in MRI-negative epilepsy. Ann Neurol 2014;75:759–70 doi:10.1002/ana.24169 pmid:24777960

    CrossRefPubMed
49. 49.↵
    2. Lüsebrink F,
    3. Wollrab A,
    4. Speck O

    . Cortical thickness determination of the human brain using high resolution 3T and 7T MRI data. Neuroimage 2013;70:122–31 doi:10.1016/j.neuroimage.2012.12.016 pmid:23261638

    CrossRefPubMedWeb of Science